READING, Pa., June 28 /PRNewswire-FirstCall/ -- Arrow
International, Inc. (NASDAQ:ARRO) today reported results for its
third fiscal quarter and nine months ended May 31, 2007. Third
Quarter Net sales for the third quarter of fiscal year 2007
increased 6.7% to $130.5 million from $122.3 million in the third
quarter of fiscal year 2006. Sales of critical care products
increased by 7.0%, primarily due to stronger sales of central
venous catheters and specialty catheters, especially arterial,
epidural and peripheral nerve block products. Sales of cardiac care
products were up 5.0% as a result of increased international sales
of intra- aortic balloons and pumps, including sales of the latest
version of the AutoCAT(R)2Wave(TM) pump and associated
FiberOptix(TM) catheter system. U.S. sales increased by 5.2% due
primarily to increased sales of specialty and central venous
catheters. International sales increased by 9.0% principally as a
result of increased sales of central venous catheters, specialty
catheters, intra-aortic balloon pumps and catheters, a $1.3 million
favorable foreign exchange impact and $0.6 million from sales by
Arrow U.K., the Company's United Kingdom (U.K.) subsidiary, due to
higher sales prices resulting from direct selling in this region
following the acquisition by the Company in April 2006 of certain
assets of its former U.K. distributor. Gross profit increased by
11.8% to $66.2 million from $59.2 million in the prior fiscal
year's third quarter, which included a charge of $1.0 million for
the step-up in cost basis of inventories acquired as part of
Arrow's purchase of certain assets of its former U.K. distributor
in April 2006. Gross margin increased to 50.7% for the third
quarter of fiscal year 2007 compared to 48.5% a year ago. Lower
manufacturing costs resulting from improved manufacturing
processes, and $0.6 million of incremental gross profit from sales
by Arrow U.K. were partially offset by changes in product and
geographic mix as a larger proportion of products were sold at
lower gross margins. Research and development (R&D) expenses
were $7.0 million or 5.4% of net sales in the third quarter of
fiscal year 2007 versus $7.2 million or 5.9% of net sales in the
same quarter of fiscal year 2006. Included in the third quarter of
fiscal year 2007 were R&D expenses for the write-off of assets
related to CorAide(TM), the Company's left ventricular assist
device licensed from the Cleveland Clinic Foundation, of $0.5
million, or approximately $0.01 diluted earnings per share,
primarily related to the property, plant and equipment that did not
have an alternative future use based upon the Company's previously
reported decision to seek an alternative approach for the
development of CorAide(TM). In addition to the aforementioned
write-off, R&D expenses related to CorAide(TM) decreased by
approximately $0.5 million when compared to the third quarter a
year ago. Selling, general and administrative (SG&A) expenses
were $35.8 million in the third quarter of fiscal year 2007, or
27.4% of net sales, compared to $32.6 million, or 26.7% of net
sales, in the third quarter of the prior fiscal year. This increase
in SG&A expenses was due in part to $0.6 million of incremental
operating expenses related to the Company's Arrow U.K. operation
and $0.9 million of legal expenses which includes patent litigation
involving the lawsuit against Datascope Corp. in which the Company
and The Johns Hopkins University were awarded a favorable judgment
on June 15, 2007. During the third quarter of fiscal year 2007 the
Company incurred a charge of $0.8 million for expenses related to
its previously announced decision to review strategic alternatives
aimed at enhancing shareholder value. This charge reduced diluted
earnings per share by approximately $0.01. Also included in the
third quarter of fiscal year 2007 results was a restructuring
charge of $0.4 million related primarily to the severance cost
associated with the Company's previously announced plan to transfer
all intra-aortic balloon catheter manufacturing from its Everett,
MA facility into existing manufacturing facilities in Hradec
Relive, Czech Republic over the next six months. As a result of the
foregoing, operating income for the third fiscal quarter increased
14.5% to $22.1 million, or 16.9% of net sales, versus $19.3
million, or 15.8% of net sales, in the third quarter of the prior
fiscal year. Income before income taxes for the third fiscal
quarter increased 11.3% to $22.7 million, or 17.4% of net sales,
versus $20.4 million, or 16.7% of net sales, in the third quarter
of the prior fiscal year. Income before tax for the third quarter
was negatively impacted by a loss of approximately $0.3 million, or
$0.005 diluted earnings per share, related to an unhedged foreign
currency position resulting from a decision to delay the
refinancing of short- term, Czech koruna-denominated indebtedness.
The Company's effective income tax rate for the third quarter of
fiscal year 2007 was 36% compared to 32% in the comparable prior
quarter. As a result of the increased income before tax and higher
income tax rate, the provision for income taxes in the third
quarter of fiscal year 2007 was $8.2 million compared to $6.5
million in the prior fiscal year quarter. The Company anticipates
its effective tax rate for the full fiscal year 2007 will be 36%.
Net income for the third quarter of fiscal year 2007 increased 4.3%
and was $14.5 million, or 11.1% of net sales, compared with $13.9
million, or 11.4% of net sales, in the prior fiscal year's third
quarter. Diluted earnings per share were $0.31 in this year's third
fiscal quarter compared to $0.31 in the prior fiscal year's third
quarter. Nine Months For the nine-month period ended May 31, 2007,
Arrow's net sales were $378.8 million, an increase of 7.5% compared
to $352.4 million in the same period of the prior fiscal year.
Operating income for the first nine months of fiscal year 2007 was
$65.4 million compared to $54.5 for the prior fiscal year. As a
result, net income increased 13.3% to $43.5 million compared to
$38.4 million in the prior fiscal year period, and diluted earnings
per share were $0.95 compared to $0.85 in the same period of the
prior year. Comments by President and CEO Commenting on the third
quarter, Arrow interim President and CEO, Philip B. Fleck said,
"Arrow's sales growth was led once again by our sales in Europe,
which grew 12.8% at constant exchange rates. Approximately 240
basis points of that increase was due to our selling direct in the
U.K., and we experienced strong growth in our central venous
catheters, specialty catheters and cardiac assist products. "Our
results for the U.S. benefited from sales of new products including
the Maximal Barrier Central Venous Access Kit and the Arrow
Pressure Injectable PICC (Peripherally Inserted Central Catheter),
which continue to be well received by our customers. The decrease
in sales in constant dollars of 1.3% in Asia/International was due
primarily to the impact of a decline in sales volume and
reimbursement for central venous catheters in Japan, and a slower
than anticipated expansion of our Chinese distributor's sales
organization. "Arrow's operating income for the quarter benefited
from an improvement in gross margin. However, our operating
expenses increased as the result of charges we took from expenses
related to the process of exploring the Company's strategic
alternatives and higher legal expenses due to litigation to defend
certain patent rights relating to some of the Company's products."
Sales and E.P.S. Targets For the full fiscal year ending August 31,
2007, the Company is targeting net sales of $512 million to $515
million. For the fourth quarter of fiscal year 2007, the Company is
targeting net sales of $133 million to $136 million based on
exchange rates in effect at the end of May 2007 and diluted
earnings per share of $0.36 to $0.39 before charges for expenses
related to the strategic alternatives valuation process and
severance costs for former executives. Excluding such special
charges and fourth quarter severance costs, the full year targets
for diluted earnings per share are $1.32 to $1.35. The targets for
the full fiscal year 2007 reflect assumptions regarding growth that
the Company believes are reasonable, but cannot assure will occur
as presently anticipated. Balance Sheet and Cash Flow Cash and
Marketable Securities on May 31, 2007 were $173.4 million, up from
$133.3 million at May 31, 2006, while short-term debt of $62.7
million increased by $11.4 million from the prior fiscal year
level. The amount of days sales outstanding increased to 75 days at
May 31, 2007 from 72 days at May 31, 2006. Inventory turns of 2.3
times per year remained relatively consistent compared to prior
year levels. Operating income, plus depreciation and amortization,
increased to $86.6 million for the first nine months of fiscal year
2007 from $74.4 million in the same period of the prior fiscal
year. Depreciation and amortization expenses were $21.2 million and
capital expenditures were approximately $23.7 million for the nine
months ended May 31, 2007. Sales Tables The table below shows sales
of Arrow critical care product platforms and cardiac care products
for the third quarter and nine months ended May 31, 2007, with
comparisons to the same prior year periods. Third Quarter Sales by
Product FY07 FY06 % %Change Platforms Change at (Dollars in
millions) Constant Exchange Rates(1) Central Venous Catheters $66.9
$63.2 5.9% 4.7% Specialty Catheters 42.7 39.2 8.9% 8.1% Non-Arrow
U.S. distributed products(3) 1.9 1.8 5.6% 5.6% Subtotal Critical
Care $111.5 $104.2 7.0% 6.1% Cardiac Care 19.0 18.1 5.0% 2.7% TOTAL
$130.5 $122.3 6.7% 5.6% Nine Months Sales by Product FY07 FY06 %
%Change Platforms Change at (Dollars in millions) Constant Exchange
Rates(2) Central Venous Catheters $196.6 $182.8 7.6% 6.8% Specialty
Catheters 121.7 111.9 8.8% 7.9% Non-Arrow U.S. distributed
products(3) 5.5 5.8 (5.2)% (5.2)% Subtotal Critical Care $323.8
$300.5 7.8% 7.0% Cardiac Care 55.0 51.9 6.0% 4.4% TOTAL $378.8
$352.4 7.5% 6.6% 1) Percentage change at constant exchange rates
are calculated by dividing third quarter fiscal year 2007 sales by
third quarter fiscal year 2006 local currency sales translated at
third quarter fiscal year 2007 exchange rates. 2) Percentage change
at constant exchange rates are calculated by dividing nine-month
fiscal year 2007 sales by nine-month fiscal year 2006 local
currency sales translated at nine-month fiscal year 2007 exchange
rates. 3) The Company purchased its New York area distributor in
September 2002 and has continued to distribute non-Arrow products
through this subsidiary. The table below shows Arrow geographical
sales for the third quarter and nine months ended May 31, 2007,
with comparisons to the same prior year periods. The weakness of
the U.S. dollar compared to same periods of last year increased the
percentage change in sales by 1.1% and 0.9% for the third quarter
and nine month periods, respectively. Third Quarter Geographical
Sales FY07 FY06 % %Change (Dollars in millions) Change at Constant
Exchange Rates(1) United States $75.4 $71.7 5.2% 5.2% Europe 30.0
24.6 22.0% 12.8% Asia/International 23.2 24.2 (4.1)% (1.3)%
Subtotal International Sales 53.2 48.8 9.0% 6.3% Subtotal Arrow
Products $128.6 $120.5 6.7% 5.6% Non-Arrow U.S. distributed
products(3) 1.9 1.8 5.6% 5.6% Total Company Sales $130.5 $122.3
6.7% 5.6% Nine Months Geographical Sales FY07 FY06 % %Change
(Dollars in millions) Change at Constant Exchange Rates(2) United
States $220.3 $209.7 5.1% 5.1% Europe 83.1 67.4 23.3% 15.3%
Asia/International 69.9 69.5 0.6% 3.1% Subtotal International Sales
153.0 136.9 11.8% 9.6% Subtotal Arrow Products $373.3 $346.6 7.7%
6.8% Non-Arrow U.S. distributed products(3) 5.5 5.8 (5.2)% (5.2)%
Total Company Sales $378.8 $352.4 7.5 % 6.6% 1) Percentage change
at constant exchange rates are calculated by dividing third quarter
fiscal year 2007 sales by third quarter fiscal year 2006 local
currency sales translated at third quarter fiscal year 2007
exchange rates. 2) Percentage change at constant exchange rates are
calculated by dividing nine-month fiscal year 2007 sales by
nine-month fiscal year 2006 local currency sales translated at
nine-month fiscal year 2007 exchange rates. 3) The Company
purchased its New York area distributor in September 2002 and has
continued to distribute non-Arrow products through this subsidiary.
Conference Call and Webcast The Company will hold a conference call
to discuss its third quarter fiscal year 2007 results today, June
28, 2007, at 4:30 pm Eastern Time. The call and simultaneous
webcast can be accessed by dialing (800)737-9483 in the U.S. and
Canada, and (706)679-7371 for international and local callers,
using ID 4875878, or by visiting
http://www.arrowintl.com/presentations/. Company Information Arrow
International, Inc. develops, manufactures and markets a broad
range of clinically advanced, disposable catheters and related
products for critical and cardiac care. The Company's products are
used primarily by anesthesiologists, critical care specialists,
surgeons, emergency and trauma physicians, cardiologists,
interventional radiologists, and other health care providers. Arrow
International's news releases and other company information can be
found on the World Wide Web at http://www.arrowintl.com/. The
Company's common stock trades on the NASDAQ Global Select
Market(SM) under the symbol ARRO. Safe Harbor Statement "Safe
Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: This news release provides historical information and
includes forward-looking statements (including projections).
Although the Company believes that the expectations in such
forward-looking statements are reasonable, the Company can give no
assurance that such expectations will prove to have been correct.
The forward-looking statements are based upon a number of
assumptions and estimates that, while presented with numerical
specificity and considered reasonable by the Company, are
inherently subject to significant business, economic and
competitive risks, uncertainties and contingencies which are beyond
the control of the Company, and upon assumptions with respect to
future business decisions which are subject to change. Accordingly,
the forward-looking statements are only an estimate, and actual
results will vary from the forward-looking statements, and these
variations may be material. Consequently, the inclusion of the
forward- looking statements should not be regarded as a
representation by the Company of results that actually will be
achieved. Forward-looking statements are necessarily speculative in
nature, and it is usually the case that one or more of the
assumptions in the forward-looking statements do not materialize.
Investors are cautioned not to place undue reliance on the
forward-looking statements. In connection with the "Safe Harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
the Company cautions the reader that, among others, the factors
below, which are discussed in the Company's Annual Report on Form
10-K for the fiscal year ended August 31, 2006, as amended, and in
its other filings with the Securities and Exchange Commission,
could cause the Company's results to differ materially from those
stated in the forward-looking statements. These factors include:
(i) stringent regulation of the Company's products by the US Food
and Drug Administration and, in some jurisdictions, by state, local
and foreign governmental authorities; (ii) the highly competitive
market for medical devices and the rapid pace of product
development and technological change in this market; (iii)
pressures imposed by the health care industry to reduce the cost or
usage of medical products and services, as well as pressures on
pricing resulting from consolidation within the medical device
industry; (iv) dependence on patents and proprietary rights to
protect the Company's trade secrets and technology, and the need
for litigation to enforce or defend these rights; (v) risks
associated with the Company's international operations; (vi)
potential product liability risks inherent in the design,
manufacture and marketing of medical devices; (vii) risks relating
to interruptions in the supply of or increases in the price of
essential raw materials or components; (viii) dependence upon
strong relationships with physicians for research, development,
marketing and sale of many of the Company's products; (ix) risks
associated with the Company's use of derivative financial
instruments; and (x) dependence on the continued service of key
members of the Company's management. Arrow International, Inc. (In
thousands, except per share amounts) (Unaudited) Three Months Ended
Nine Months Ended Consolidated Statements of Income Data: May 31,
May 31, May 31, May 31, 2007 2006 2007 2006 Net sales $130,496
$122,257 $378,818 $352,405 Cost of goods sold 64,354 63,023 187,562
180,225 Gross profit 66,142 59,234 191,256 172,180 Operating
expenses: Research and development 7,034 7,199 20,384 20,708
Selling, general and administrative 35,797 32,602 103,700 97,081
Special charges 789 - 1,090 - Restructuring charges 431 130 714
(126) Total operating expenses 44,051 39,931 125,888 117,663
Operating income 22,091 19,303 65,368 54,517 Interest, net (1,287)
(912) (3,616) (2,059) Other (income) expenses, net 708 (219) 1,085
(101) Income before income taxes 22,670 20,434 67,899 56,677
Provision for income taxes 8,162 6,535 24,444 18,314 Net income
$14,508 $13,899 $43,455 $38,363 Basic earnings per common share
$0.32 $0.31 $0.96 $0.86 Diluted earnings per common share $0.31
$0.31 $0.95 $0.85 Weighted average shares used in computing basic
earnings per common share 45,169 44,810 45,071 44,729 Weighted
average shares used in computing diluted earnings per common share
45,692 45,281 45,608 45,242 Consolidated Balance Sheet: May 31
August 31, 2007 2006 ASSETS Cash and cash equivalents $160,174
$148,576 Marketable securities 13,179 9,783 Receivables (net)
104,809 96,937 Inventories 113,954 102,901 Prepaid expenses and
other 25,966 31,023 Total current assets 418,082 389,220 Property,
plant and equipment (net) 181,067 173,853 Other assets 127,087
134,364 Total assets $726,236 $697,437 LIABILITIES AND
SHAREHOLDERS' EQUITY Notes payable and lines of credit $62,748
$70,979 Other current liabilities 74,683 66,113 Current maturities
of long-term debt 973 995 Other liabilities 31,533 33,802 Total
liabilities 169,937 171,889 Total shareholders' equity 556,299
525,548 Total liabilities and shareholders' equity $726,236
$697,437 DATASOURCE: Arrow International, Inc. CONTACT: Frederick
J. Hirt, CFO of Arrow International, Inc., +1-610-478-3117 Web
site: http://www.arrowintl.com/
http://www.arrowintl.com/presentations
Copyright
Arrow (NASDAQ:ARRO)
過去 株価チャート
から 5 2024 まで 6 2024
Arrow (NASDAQ:ARRO)
過去 株価チャート
から 6 2023 まで 6 2024